



**BRAF+ mutations have been identified
in approximately half of melanoma patients^{1,2}**

In BRAF V600+ melanoma patients

^{Pr}TAFINLAR® + ^{Pr}MEKINIST®, as monotherapy or in combination, are indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

TAFINLAR® + MEKINIST®, in combination, are indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection.

**Start with
TAFINLAR® ⊕ MEKINIST®**

Please consult the Product Monographs at www.novartis.ca/tafinlarmonograph and www.novartis.ca/mekinistmonograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monographs are also available through our medical department. To report an adverse event, please call **1-800-363-8883**.

References: 1. TAFINLAR® Product Monograph. Novartis Pharmaceuticals Canada Inc. December 11, 2019. 2. MEKINIST® Product Monograph. Novartis Pharmaceuticals Canada Inc. December 6, 2019.



Novartis Pharmaceuticals Canada Inc.
Dorval, Québec H9S 1A9
www.novartis.ca
☎ 514.631.6775 📠 514.631.1867

TAFINLAR® and MEKINIST® are registered trademarks.
Product Monographs available on request.
Printed in Canada
March/2020 – PRO/MTF/0071E
© Novartis Pharmaceuticals Canada Inc. 2020

